Treatment of obsessive-compulsive disorder by U.S. psychiatrists

Simple item page
dc.contributor.authorBlanco C.
dc.contributor.authorOlfson M.
dc.contributor.authorStein D.J.
dc.contributor.authorSimpson H.B.
dc.contributor.authorGameroff M.J.
dc.contributor.authorNarrow W.H.
dc.date.accessioned2011-05-15T16:01:56Z
dc.date.available2011-05-15T16:01:56Z
dc.date.issued2006
dc.description.abstractObjective: To examine the treatment of obsessive-compulsive disorder (OCD) by a nationally representative sample of psychiatrists. Method: The authors analyzed physician-reported data from the 1997 and 1999 American Psychiatric Institute for Research and Education Practice Research Network (PRN) Study of Psychiatric Patients and Treatments to describe demographic, clinical, and treatment characteristics of patients with a diagnosis of OCD (per DSM-IV and clinical features). On the basis of published studies, serotonin reuptake inhibitor (SRI) doses were predefined as low, intermediate, or high. Results: Sixty-five percent of patients received an SRI, but only 39.4% of the sample patients received an SRI at a dose thought to be most effective for OCD or were having their dose titrated. A total of 7.5% of patients in the sample received cognitive-behavioral therapy (CBT) with or without medication treatment. Prescription of benzodiazepines or antipsychotics was common, often in the absence of an SRI. Patients receiving CBT had on average the highest scores on the Global Assessment of Functioning Scale. No other demographic or treatment characteristics were associated with the type of treatment received by the patients. Conclusion: Despite important advances in the efficacy of pharmacologic and psychological treatments for OCD, psychiatric care of OCD continues to be an area with substantial opportunity for quality improvement.
dc.description.versionArticle
dc.identifier.citationJournal of Clinical Psychiatry
dc.identifier.citation67
dc.identifier.citation6
dc.identifier.issn1606689
dc.identifier.urihttp://hdl.handle.net/10019.1/12226
dc.subjectbenzodiazepine
dc.subjectcitalopram
dc.subjectclomipramine
dc.subjectfluoxetine
dc.subjectfluvoxamine
dc.subjectneuroleptic agent
dc.subjectparoxetine
dc.subjectserotonin uptake inhibitor
dc.subjectsertraline
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbehavior therapy
dc.subjectchild
dc.subjectfemale
dc.subjecthuman
dc.subjectinfant
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectObsessive-compulsive disorderen_ZA
dc.subjectpriority journal
dc.subjectpsychiatrist
dc.subjectUnited States
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectHealth Care Surveys
dc.subjectHumans
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPhysician's Practice Patterns
dc.subjectRetrospective Studies
dc.subjectSerotonin Uptake Inhibitors
dc.subjectUnited States
dc.titleTreatment of obsessive-compulsive disorder by U.S. psychiatrists
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications